KMB Looks 13.5% Undervalued on GF Value™ with Solid Dividend Yie

The ACCC approved Kimberly-Clark's acquisition of Kenvue, contingent on divesting Kenvue's Carefree and Stayfree brands in Australia. The move aims to maintain competition in the menstrual care market. The deal, announced in 2025, values Kenvue at $48.7bn.

Kimberly-Clark has received conditional approval from Australia for its acquisition of Kenvue. The company's stock is currently trading at 19.02 USD, with a 5-day change of +1.41% and a year-to-date change of +10.46%.

The ACCC approved Kimberly-Clark's acquisition of Kenvue, requiring the sale of Carefree and Stayfree brands to maintain competition in Australia's period care market. Both companies supply period care products, and the deal reduces major suppliers from three to two. This is the fourth conditional approval under Australia's new merger control regime.

Kimberly-Clark's acquisition of Kenvue has been approved in Australia with conditions. The Australian Competition & Consumer Commission requires Kimberly-Clark to divest Kenvue’s Carefree and Stayfree brands to maintain competition in the period care market. Both companies are major suppliers in Australia.

Kimberly-Clark (KMB) has requested EU approval for its $40 billion acquisition of Kenvue, the maker of Tylenol. The deal, announced in November 2023, is expected to close in late 2026. Kimberly-Clark anticipates $2.1 billion in annual cost savings and $32 billion in combined annual revenues. The acquisition includes brands like Listerine, Aveeno, and Neutrogena.

Kimberly-Clark seeks EU approval for its $40bn acquisition of Kenvue, aiming to create a consumer health and personal care giant with $32bn annual revenue. The deal, announced last November, targets $2.1bn in annual cost savings. EU regulators will assess competition concerns, with a decision pending. The acquisition would expand Kimberly-Clark's portfolio to include brands like Tylenol, Listerine, and Neutrogena.